Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05328102 |
| Title | Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Xencor, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | FRA | ESP |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Swedish Cancer Center | Seattle | Washington | 98104 | United States | Details | |
| CHU de Rennes - Hopital de Pontchaillou | Rennes Cedex | France | Details | |||
| Hospital Universitario Virgen de las Nieves | Granada | Spain | Details |